Mai

Genetic Analysis Systems Enter the Clinical Mainstream

Like many other diagnostic regimes that were previously restricted to large specialty laboratories, genetic analysis is entering the clinical mainstream. Smaller, simpler analyzer systems are now suitable and affordable for hospital or large physicians group labs, while some genetic test kits are becoming available for primary point of care locations such as clinics and physician offices.<...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposiumof Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation today announced the presentation of findingsfrom the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)study program database showing a statistically significantrelationship between the duration of time spent...

Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., announced today the publication of clinicaldata highlighting the ability of Glufast(R) (mitiglinide calciumhydrate) monotherapy, or combination therapy with metformin, tomanage glucose surges before and after meals. The data werepublished in the Abstract Book for the American DiabetesAssociation 67th Annual Scien...

Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo

Demonstrates Positive Effect on Objective and Subjective SleepMeasures MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- Accordingto study results presented today at SLEEP 2007, the 21st annualmeeting of the Associated Professional Sleep Societies (APSS),VEC-162, a balanced melatonin (MT1/MT2) receptor agonist beingdeveloped by Vanda Pharmaceuticals Inc. , demonstrated improvementsin...

Medivation's Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimer's Disease Trial After One Year of Therapy

- Aggregate Benefit over Placebo Larger at One Year than at SixMonths - SAN FRANCISCO and WASHINGTON, June 11, 2007/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that thebenefits of Dimebon over placebo in its double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer'sdisease were statistically significant on all five study endpointsat 12 months. Importantl...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

CHICAGO - June 3, 2007 - Schering-Plough Corp. announced resultsfrom a Phase III study that showed maintenance chemotherapy withCaelyx (pegylated liposomal doxorubicin hydrochloride)significantly prolonged time to progression (TTP) in patients withmetastatic breast cancer with infrequent and manageable clinicaltoxicity after first-line chemotherapy. These data were presentedtoday at the...

Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow

GAITHERSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ -- IomaiCorporation today announced that it will announce results from thePhase 1 trial of its patch-based needle-free influenza vaccinebefore the markets open tomorrow. A conference call and livewebcast will be held at 8:30 a.m. Eastern Time tomorrow to discussthe results. To access the live conf...

Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up

Separate Survey Underscores Impact of Disease on Work Status andProductivity WASHINGTON, May 23, 2007 /PRNewswire-FirstCall/ -- Findingspresented today at Digestive Disease Week(R) 2007 (DDW), fromlong-term extensions of the ACT trials (Active Ulcerative Colitis 1& 2) show that subjects with moderately to severely activeulcerative colitis (UC) who had responded to REMICADE(R)(inflixi...

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent

Moffitt Research Presented at 9th International Symposium onMyelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated resultsfrom a pivotal Phase II trial evaluating Revlimid in patients withan incurable blood cancer known as myelodysplastic syndromes (MDS)were presented today by Dr. Alan List, from the H. Lee MoffittCancer Center & Research Institute, at the 9th...

Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers' Diarrhea Stimulates Immune Response Even at Low Doses

-- Data Gathered to Assist in Design of Future Trials, OtherPrograms -- GAITHERSBURG, Md. and LISBON, Portugal, April 26, 2007/PRNewswire-FirstCall/ -- Iomai Corporation today announced resultsfrom a 400-patient, Phase 2 dose-ranging trial of its patch-basedvaccine for travelers' diarrhea. The trial was conducted to assessthe ability of a range of vaccine doses to generate an immunerespo...

Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer

PALO ALTO, Calif., April 17, 2007 /PRNewswire-FirstCall/ --Telik, Inc. announced the presentation today of results from aPhase 2 clinical trial of the triplet combination of TELCYTA(R)(canfosfamide HCl, TLK286), carboplatin and paclitaxel in thefirst-line treatment of advanced non-small cell lung cancer. Theresults include highly statistically and clinically significantimprovement in bot...

Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control

52-Week Trial Maintained Improvement in Personal and SocialPerformance COLORADO SPRINGS, Colo., March 30, 2007 /PRNewswire/ --Longer-term treatment with INVEGA(TM) (paliperidone)Extended-Release Tablets, a new once daily oral medication forschizophrenia, helped many patients effectively control theirsymptoms and maintain their improvements in personal and socialfunctioning....

BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality

JERUSALEM--(BUSINESS WIRE)--Mar 7, 2007 - BioLineRx Ltd.(TASE:BLRX), Israel's leading drug development company, reportedtoday pre-clinical data from trials of BL-1040 demonstrating thatBL-1040 is effective in preventing deterioration of the myocardiumafter a myocardial infarction (MI), thereby reducing left ventricledilatation and eventual heart failure in a pig model. ProfessorJonathan Leo...